Literature DB >> 1375481

Definition of immunogenic determinants of the human papillomavirus type 16 nucleoprotein E7.

A Altmann1, I Jochmus-Kudielka, R Frank, H Gausepohl, U Moebius, L Gissmann, S C Meuer.   

Abstract

Specific T lymphocyte lines and T cell clones were established from peripheral blood mononuclear cells of asymptomatic seropositive individuals employing synthetic peptides which correspond to the sequence of the human papillomavirus (HPV) type 16 transforming protein E7. Specificity analysis of T cells as determined by means of [3H] thymidine incorporation after stimulation with individual peptides revealed three immunogenic determinants of E7 that are recognised in association with at least two different HLA haplotypes. One N-terminal region (aminoacids 5-18) was recognised by one T cell line. T cell clones and the corresponding T cell line established from another donor responded to a different N-terminal (17-38) and to a C-terminal region (69-86). The N-terminal sequence 5-18 and the C-terminal determinant contain a periodicity of hydrophilic and hydrophobic residues that have been found in many T cell epitopes. Phenotypic characterisation of T cell clones by indirect immunofluorescence revealed that the T cell clones expressed the CD4 surface glycoprotein suggesting that the specific E7 determinants were recognised in association with major histocompatibility complex (MHC) class II molecules. With regard to functional properties, at least three T cell clones exhibited specific cytotoxic activity towards autologous B lymphocytes transformed by Epstein-Barr virus in the presence of the relevant HPV16 E7 peptides. The implications of these results regarding the development of vaccination strategies and host-virus interaction are discussed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1375481     DOI: 10.1016/s0959-8049(05)80047-4

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  10 in total

1.  Human papillomavirus type 16 E7 DNA vaccine: mutation in the open reading frame of E7 enhances specific cytotoxic T-lymphocyte induction and antitumor activity.

Authors:  W Shi; P Bu; J Liu; A Polack; S Fisher; L Qiao
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

2.  T-cell proliferative response to human papillomavirus type 16 peptides: relationship to cervical intraepithelial neoplasia.

Authors:  M Nakagawa; D P Stites; S Farhat; A Judd; A B Moscicki; A J Canchola; J F Hilton; J M Palefsky
Journal:  Clin Diagn Lab Immunol       Date:  1996-03

3.  Isolation and characterization of human papillomavirus type 6-specific T cells infiltrating genital warts.

Authors:  K Hong; C E Greer; N Ketter; G Van Nest; X Paliard
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

4.  Human papillomavirus type 33 E7 peptides presented by HLA-DR*0402 to tumor-infiltrating T cells in cervical cancer.

Authors:  H Höhn; H Pilch; S Günzel; C Neukirch; K Freitag; A Necker; M J Maeurer
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

5.  Production and characterization of human proliferative T-cell clones specific for human papillomavirus type 1 E4 protein.

Authors:  J C Steele; T Stankovic; P H Gallimore
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

6.  A vaccine conjugate of 'ISCAR' immunocarrier and peptide epitopes of the E7 cervical cancer-associated protein of human papillomavirus type 16 elicits specific Th1- and Th2-type responses in immunized mice in the absence of oil-based adjuvants.

Authors:  R W Tindle; S Croft; K Herd; K Malcolm; A F Geczy; T Stewart; G J Fernando
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

Review 7.  Immunomanipulative strategies for the control of human papillomavirus associated cervical disease.

Authors:  R W Tindle
Journal:  Immunol Res       Date:  1997       Impact factor: 4.505

8.  Potent, Selective CARs as Potential T-Cell Therapeutics for HPV-positive Cancers.

Authors:  Xueyin Wang; Mark L Sandberg; Aaron D Martin; Kathleen R Negri; Grant B Gabrelow; Daniel P Nampe; Ming-Lun Wu; Michele E McElvain; Dora Toledo Warshaviak; Wen-Hua Lee; Julyun Oh; Mark E Daris; Falene Chai; Christine Yao; James Furney; Craig Pigott; Alexander Kamb; Han Xu
Journal:  J Immunother       Date:  2021-10-01       Impact factor: 4.456

9.  Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours.

Authors:  F V Cromme; P F van Bommel; J M Walboomers; M P Gallee; P L Stern; P Kenemans; T J Helmerhorst; M J Stukart; C J Meijer
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

10.  T-cell responses to human papillomavirus type 16 among women with different grades of cervical neoplasia.

Authors:  J C Steele; C H Mann; S Rookes; T Rollason; D Murphy; M G Freeth; P H Gallimore; S Roberts
Journal:  Br J Cancer       Date:  2005-07-25       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.